English  |  正體中文  |  简体中文  |  Items with full text/Total items : 27287/39131
Visitors : 2442769      Online Users : 29
RC Version 4.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister

Please use this identifier to cite or link to this item: http://ntour.ntou.edu.tw:8080/ir/handle/987654321/39349

Title: Combination of two targeted medications (Bevacizumab Plus Cetuximab) improve the therapeutic response of pancreatic carcinoma
Authors: Hung-Yi Chiou
Cheng-Jeng Tai
Ming-Te Huang
Chih-Hsiung Wu
Chien-Kai Wang
Chen-Jei Tai
Chun-Chao Chang
Cheng-I. Hsieh
Yu-Jia Chang
Chang-Jer Wu
Li-Jen Kuo
Po-Lei Wei
Ray-Jade Chen
Contributors: 國立臺灣海洋大學:食品科學系
Date: 2016-04
Issue Date: 2016-12-07T02:20:49Z
Publisher: Medicine (Baltimore)
Abstract: Abstract: The objective of this study is to evaluate the efficacy and safety profiles of the targeted medications, bevacizumab and cetuximab, in combination with cytostatic drugs in patients with locally advanced or metastatic pancreatic cancer. In this retrospective phase 2 study, a total of 59 patients with pancreatic cancer were recruited and received conventional (gemcitabine, cisplatin, and fluorouracil) or targeted regimen (conventional plus bevacizumab and cetuximab for the first cycle) in 2-week intervals for four cycles. The primary end-point for this study was the overall response rate. Secondary end-points were progression-free survival and the safety profiles of the combined therapy. The median time-to-progression and overall survival were 3 and 7 months, respectively, in the conventional treatment group as well as 11 and 13 months, respectively, in the targeted medications treatment group. The most common adverse events in both treatment groups were nausea and vomiting. Moderate (Grade 2) nausea and vomiting were more common in the conventional group than the targeted group but severe (Grade 3) nausea and vomiting were more common in the targeted group. Bevacizumab and cetuximab in combination with gemcitabine, cisplatin, and fluorouracil may help lengthen overall survival up to six months for patients with pancreatic cancer.
Relation: 95(15)
URI: http://ntour.ntou.edu.tw:8080/ir/handle/987654321/39349
Appears in Collections:[食品科學系] 期刊論文

Files in This Item:

File Description SizeFormat
index.html0KbHTML91View/Open


All items in NTOUR are protected by copyright, with all rights reserved.

 


著作權政策宣告: 本網站之內容為國立臺灣海洋大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,請合理使用本網站之內容,以尊重著作權人之權益。
網站維護: 海大圖資處 圖書系統組
DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback